Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Replicel Life Sciences Inc
(OP:
REPCF
)
0.0058
UNCHANGED
Last Price
Updated: 3:49 PM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,500
Open
0.0058
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0058
Today's Range
0.0058 - 0.0058
52wk Range
0.0010 - 0.0778
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
RepliCel Provides Corporate Update
November 28, 2022
Via
ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
August 04, 2022
Via
ACCESSWIRE
Performance
YTD
-84.15%
-84.15%
1 Month
+480.00%
+480.00%
3 Month
+480.00%
+480.00%
6 Month
+480.00%
+480.00%
1 Year
-87.79%
-87.79%
More News
Read More
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
August 02, 2022
Via
ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Material Patent Milestones
January 10, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
December 21, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Terminates License Agreement with Shiseido
December 21, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
November 11, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
November 09, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
October 28, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Dermal Injector Update
October 27, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
October 18, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
October 12, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Economy
Exposures
Economy
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
September 16, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
July 07, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Adds Independent Director
June 15, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
RepliCel Launches Testing of Dermal Injector Units
May 25, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
May 19, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
May 17, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
May 11, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
